Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
RemeGen’s RC88 Receives US FDA Fast Track Designation
FDA Grants IND Approval to RemeGen's RC88 for Phase II Ovarian Cancer ...
Abstract 2862: Anti MSLN ADC RC88 engages unique binding to target ...
RC88 Gets Fast Track Designation for Gynecologic Cancer Treatment
Rong Chang Bio: A new clinical development of ADC drug RC88 combined ...
RC88
荣昌生物ADC RC88获美国FDA快速通道资格 - 知乎
Antibody–drug conjugates: Smart chemotherapy delivery across tumor ...
荣昌生物靶向MSLN ADC新药RC88获美国FDA快速通道资格，治疗卵巢癌等肿瘤
最新16款1类新药获批临床！阿斯利康、齐鲁制药、荣昌生物在内_摩熵医药(原药融云)
荣昌生物ADC新药RC88联合特瑞普利单抗治疗晚期恶性实体瘤获批I/IIa临床 - 脉脉
Frontiers | A review of recent advances on single use of antibody-drug ...
Concentration versus time profiles of RC88. (a) Observed and model ...
Preclinical safety profile of RC88-ADC：a novel mesothelin-targeted ...
荣昌生物ADC RC88获美国FDA快速通道资格，靶向MSLN，治疗卵巢癌等肿瘤医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
RemeGen and Innovent Collaborate on Clinical Trials to Evaluate the ...
荣昌生物ADC注射用RC88与信达生物PD-1抑制剂联合用药获批临床
荣昌生物靶向MSLN ADC药物RC88在美国获批2期临床，治疗妇科肿瘤
Frontiers | Antibody-drug conjugates: the clinical development in ...
Antibody–drug conjugates for cancer therapy - The Lancet Oncology
An Overview of the Development and Preclinical Evaluation of Antibody ...
Importance and Considerations of Antibody Engineering in Antibody-Drug ...
Antibody–drug conjugates: in search of partners of choice: Trends in Cancer
Antibody–drug conjugates - Bioanalysis Zone
Antibody-drug conjugates as novel anti-cancer chemotherapeutics ...
Antibody drug conjugates in non-small cell lung cancer: An emerging ...
AACR2025：抗MSLN抗体偶联药物RC88通过独特结合靶向阳性肿瘤细胞且受可溶性MSLN蛋白干扰更小 - 知乎
Antibody-drug conjugates in NSCLC with actionable genomic alterations ...
Antibody-Drug Conjugates: Functional Principles and Applications in ...
Antibody–Drug Conjugates for Multiple Myeloma: Just the Beginning, or ...
Antibody Drug Conjugates in Lung Cancer: State of the Current ...
Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical ...
Antibody-drug conjugates combinations in cancer treatment - PMC
Characterization of RC68-based ADCs. a Molecular structures of ...
Model‐Informed Therapeutic Dose Optimization Strategies for Antibody ...
Antibody-Drug Conjugate Targeting c-Kit for the Treatment of Small Cell ...
荣昌生物ADC RC88与信达生物PD-1信迪利单抗一项联合用药研究获批
荣昌生物ADC新药RC88联合特瑞普利单抗治疗晚期恶性实体瘤获批I/IIa临床 - 动点科技
Antibody-drug Conjugates: A Novel Paradigm for Cancer Therapy | Drug ...
Key metrics to expanding the pipeline of successful antibody–drug ...
Balb/c nude mice were treated with the vehicle, RC88. (a)... | Download ...
Antibody-Drug Conjugates for the Therapy of Thoracic Malignancies ...
荣昌生物制药（烟台）股份有限公司_荣昌生物
A highly stable human single-domain antibody-drug conjugate exhibits ...
获批临床！荣昌生物ADC RC88与信达生物PD-1信迪利单抗一项联合用药研究最新动态_药智新闻
Antibody-drug conjugates with dual payloads for combating breast tumor ...
Antibody-Drug Conjugates: Manufacturing Challenges and Trends
Current Analytical Strategies for Antibody–Drug Conjugates in Biomatrices
Antibody Drug Conjugates for Cancer Therapy - Pharmacological Reviews
How Far Have We Developed Antibody–Drug Conjugate for the Treatment of ...
Design of antibody-drug conjugates. (a) Schematic of the components of ...
The Future of Antibody–Drug Conjugates in Urothelial Cancer - Advances ...
Full article: Antibody-drug conjugates for non-oncological indications
Development of antibody‐drug conjugates in cancer: Overview and ...
Antibody–Drug Conjugates in HR+ Breast Cancer: Where Are We Now and ...
全球及中国RA患病人数及预测（万人） - 2024年06月 - 行业研究数据 - 小牛行研
Preclinical Pharmacokinetic Considerations for the Development of ...
Unveiling the power of antibody-drug conjugates | CAS
Antibody-drug conjugate combinations in cancer treatment: clinical ...
New day for antibody-drug conjugates
1310 Supporting dose decisions for antibody drug conjugates (ADC ...
Antibody–Drug Conjugates: Perspectives and Characterization ...
An Insight into FDA Approved Antibody-Drug Conjugates for Cancer ...
Antibody-drug conjugates—an emerging class of cancer treatment - PMC
Antibody-drug Conjugate Information | ADCdb
Antibody–drug conjugates in lung and breast cancer: current evidence ...
Delivery of Drugs into Cancer Cells Using Antibody–Drug Conjugates ...
Antibody-drug conjugates | Scientist Live
Development of a facile antibody–drug conjugate platform for increased ...
Antibody–Drug Conjugates: The Last Decade
Antibody–Drug Conjugates and Beyond: Next-Generation Targeted Therapies ...
Directions for Next Generation Antibody-Drug Conjugates
ASCO 2019: A Phase II Study of Investigational Antibody-drug Conjugate ...
Antibody–drug conjugates treatment of small cell lung cancer: advances ...
Exploring Experimental and In Silico Approaches for Antibody–Drug ...
Innovations in Antibody-Drug Conjugate (ADC) in the Treatment of Lymphoma
ASCO2024｜荣昌生物公布MSLN靶向 ADC药物RC88 I/II期临床研究数据医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
荣昌生物现涨超4% RC88治疗妇瘤的II期临床试验申请获FDA许可|荣昌生物_新浪财经_新浪网
DelveInsight Evaluates a Robust Antibody-drug Conjugates in
Antibody–drug conjugates: Recent advances in payloads - PMC
New Technique Simplifies Antibody Drug Conjugate Design | Biocompare.com
Antibody–Drug Conjugates in the Pipeline for Treatment of Melanoma ...
Advancing Antibody–Drug Conjugates: Precision Oncology Approaches for ...
‘Targeting’ Improved Outcomes with Antibody-Drug Conjugates in Non ...
Antibody-Drug Conjugates in Breast Cancer: Searching for Magic Bullets ...
Antibody Drug Conjugate (ADC) Load Characterization and Analysis Using ...
The Surge and Impact of Antibody-Drug Conjugates (ADCs) in Modern Oncology
Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for ...
18P: Telisotuzumab vedotin monotherapy in patients with previously ...
Harnessing computational technologies to facilitate antibody-drug ...
Recent Technological and Intellectual Property Trends in Antibody–Drug ...
Antibody drug conjugates currently in clinical development a ...
antibody-drug conjugates product brochure | PPT
Figure 1 from Antibody–Drug Conjugates for the Treatment of Breast ...
